
Please try another search
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.
Name | Age | Since | Title |
---|---|---|---|
Arkadiusz Miazek | - | - | Member of Scientific Board |
Maciej Przewozny | - | - | Member of Scientific Board |
Ewa Wieclawik | - | 2022 | Vice Chairman of Supervisory Board |
Andrzej Jan Grabinski-Baranowski | - | 2022 | Member of Supervisory Board |
Ewelina Pawlus-Czerniejewska | - | 2022 | Chairman of Supervisory Board |
Maciej Wieloch | - | - | Member of Supervisory Board |
Aleksandra Klimczak | - | - | Member of Scientific Board |
Wojciech Aksman | - | - | Member of Supervisory Board |
Piotr Lembas | 35 | 2022 | Member of Supervisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review